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Abstract: Patients with chronic obstructive pulmonary disease (COPD) present with a variety 
of symptoms and pathological consequences. Although primarily viewed as a respiratory dis-
ease, COPD has both pulmonary and extrapulmonary effects, which have an impact on many 
aspects of physical, emotional, and mental well-being. Traditional assessment of COPD relies 
heavily on measuring lung function, specifically forced expiratory volume in 1 second (FEV
1
). 
However, the evidence suggests that FEV
1
 is a relatively poor correlate of symptoms such as 
breathlessness and the impact of COPD on daily life. Furthermore, many consequences of the 
disease, including anxiety and depression and the ability to perform daily activities, can only be 
described and reported reliably by the patient. Thus, in order to provide a comprehensive view 
of the effects of interventions in clinical trials, it is essential that spirometry is accompanied by 
assessments using patient-reported outcome (PRO) instruments. We provide an overview of 
patient-reported outcome concepts in COPD, such as breathlessness, physical functioning, and 
health status, and evaluate the tools used for measuring these concepts. Particular attention is 
given to the newly developed instruments emerging in response to recent regulatory guidelines 
for the development and use of PROs in clinical trials. We conclude that although data from 
the development and validation of these new PRO instruments are emerging, to build the body 
of evidence that supports the use of a new instrument takes many years. Furthermore, new 
instruments do not necessarily have better discriminative or evaluative properties than older 
instruments. The development of new PRO tools, however, is crucial, not only to ensure that 
key COPD concepts are being reliably measured but also that the relevant treatment effects 
are being captured in clinical trials. In turn, this will help us to understand better the patient’s 
experience of the disease.
Keywords: patient-reported outcomes, chronic obstructive pulmonary disease, health-related 
quality of life, questionnaire development, dyspnea, exacerbations
Introduction
Chronic obstructive pulmonary disease (COPD) is a complex disease characterized 
by multiple symptoms that place a substantial burden on patients’ health and health 
care systems.1 The effectiveness of treatments in COPD has traditionally been mea-
sured by changes in forced expiratory volume in one second (FEV
1
).2 Spirometry has 
a central role in diagnosis, but it does not reliably reflect the burden of COPD on a 
patient’s health status. The change in FEV
1
 is only modestly associated with change 
in health status or other patient-reported outcomes (PROs),3–5 which may be a reflec-
tion of how individuals experience differing effects on health status, despite the same 
physiological limitations.5 Furthermore, other symptoms of COPD such as cough 
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and extrapulmonary effects of the disease are not reflected 
by spirometry,6 the consequences of which may be better 
captured from the patient’s perspective. Cough and sputum 
production, for example, can have physical, emotional, and 
social effects on the patient,7 and skeletal muscle dysfunc-
tion, one of the extrapulmonary effects of the disease, can 
contribute significantly to impaired exercise capacity, in turn 
affecting a patient’s health status.8 Thus, in order to provide 
a comprehensive view of the effects of interventions in clini-
cal trials, it is essential that spirometry be accompanied by 
assessments using PRO instruments.4,9
PROs are outcomes reported directly by patients, usually 
by self-administered questionnaire or diary. In this way, 
they capture the individual’s experiences of COPD without 
any interpretation from third parties, such as health care 
 providers. Occasionally, proxies such as relatives can provide 
information on patient outcomes when a patient’s cognition 
or health is severely impaired. However, such responses 
should be interpreted with care, given that proxy reporting 
is susceptible to underestimation or overestimation of health 
status impairment, compared with the responses of patients 
themselves.10–12
PROs present the patient perspective, quantifying 
the extent to which the physiological effects of the dis-
ease impact on health and functioning. Key concepts in 
 understanding the impact of COPD from the patient’s 
 perspective include breathlessness, fatigue, cough and 
sputum production, physical functioning, social function-
ing, and exacerbations (Figure 1), given that these features 
of the disease often have the greatest impact on patients’ 
lives.1 This literature review was undertaken to provide an 
overview of PRO concepts in COPD and the instruments 
used to evaluate these concepts. The literature was searched 
to retrieve articles describing tools for measuring outcomes 
in COPD and the development and use of instruments 
and PRO measures for assessing symptoms, health status, 
functioning, and quality of life. Due to the wide scope of 
the literature and large number of possible search terms, 
a fully systematic approach was not employed and search 
terms were not prespecified. Articles were included in 
the review based on the results of ad hoc searches of the 
PubMed database conducted during May and June 2011, the 
authors’ knowledge of the literature, and from the reference 
lists of retrieved articles.
Development and use of PRO 
instruments
There are a number of tools available for capturing PRO 
data. Newly developed tools address the relevant concepts 
and aspects of patients’ lives beyond measuring FEV
1
 and 
Influences/risk factors/modifiers Components of patient experienceKey features of COPD
Exposure to
environmental factors
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Exertion
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Low physical activity
Altered mental state
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Comorbidity
Poor social support
Previous exacerbations
Dyspnea
Airflow limitation
Dyspnea and fatigue
Functional impairment
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Fatigue
Activity modification
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Mood state changes
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Hospitalization
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Mortality risk
Figure 1 Conceptual model of chronic obstructive pulmonary disease and the patient’s experiences of the key features of the condition.103–107
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have been developed to measure treatment benefit in a way 
that will satisfy regulatory requirements.
In order to capture the effects of therapies that are rel-
evant to patients with COPD, PRO instruments need to be 
fit for purpose, valid, reliable, and responsive to clinically 
meaningful treatment effects, understandable to patients and 
physicians with easily interpreted scoring systems, relevant to 
health care providers, and acceptable to regulatory  authorities. 
PRO tools that fulfil these criteria may help to advance drug 
development by increasing our understanding of the efficacy 
and safety of new therapies. Recent guidance on the devel-
opment and use of PRO instruments has been prepared by 
the US Food and Drug Administration (FDA),13,14 which 
represents the FDA’s current thinking on the use of PRO 
instruments to support labeling claims for medical products. 
The guidelines describe the characteristics of a PRO instru-
ment that the FDA will look for to determine the adequacy 
of the instrument to support the claims made in product 
labeling where PRO data are being used. According to these 
new guidelines, for a PRO instrument to be acceptable to 
regulatory authorities, there must be evidence that there 
was patient input during item generation and testing, and 
that the instrument reliably measures the concept of interest 
in the target population. Consideration will be given to the 
conceptual framework underlying the design of the instru-
ment and its measurement properties (reliability, validity, and 
ability to detect change), which should be well established 
prior to enrolling patients into confirmatory clinical trials 
of new drugs.
Many of the existing PRO tools available for use in COPD 
patients were developed before this regulatory guidance 
was introduced. PRO tools that predate the FDA PRO 
guidance13 sometimes lack a clear, well defined conceptual 
framework, or may lack the qualitative foundation of items 
generated from patient interviews. However, this should 
be set against the existence of a well documented body of 
literature detailing the validity, reliability, and responsive-
ness of such instruments that may have been built up over 
many years of use. The lack of standardized and accepted 
PRO tools for assessing the different aspects of COPD can 
hinder accurate evaluation of the efficacy of new therapies. 
New PRO instruments are therefore being designed to tackle 
concepts in COPD that have not previously been evalu-
able. Several of these are being developed in large-scale 
collaborations, such as the European Innovative Medicines 
Initiative PROactive tools and EXAcerbations of COPD 
Tool (EXACT).15–17 These initiatives aim to improve PRO 
development and evaluation through cooperation between 
experts from the pharmaceutical industry, academia, and 
regulatory authorities.
Other PRO instruments are also in development for the 
evaluation of specific concepts and to support claims about 
benefits with a particular treatment. These include the Short-
ness of Breath with Daily Activity questionnaire (SOBDA), 
and the Capacity of Daily Living during the Morning 
(CDLM) questionnaire.18,19
Attributes of effective PRO 
instruments that are fit for purpose
A PRO can be regarded as a latent construct in the sense that 
it is not directly measurable but relies upon indicators that can 
be quantified, such as a patient’s self-reported symptoms.20 
How well items in a PRO tool contribute to the concept being 
measured can be assessed using Rasch modeling,21 which is 
recognized as an effective application of modern psycho-
metric testing for the development of new PRO instruments. 
This mathematical modeling tests how well an instrument 
conforms to a unidimensional model, and ensures that these 
instruments perform equally for all respondents, a concept 
termed “invariance”.22 An important function of Rasch analy-
sis is the transformation of an ordinal raw score (ie, patient 
responses) into a linear, interval-level variable, ultimately 
producing a linear scale (eg, 0–100).20 The Rasch model can 
also be used to compare the quality of fit of items measured 
individually and when tested together.23 The quality of fit 
to a Rasch unidimensional model will determine whether 
the instrument has true interval scaling properties; in other 
words, whether the instrument behaves like a ruler, against 
which all patients can be measured (by the same standard). 
When a disease-specific instrument has true interval scaling 
properties, it may be sensitive to small treatment effects 
across a broad range of disease severity.2
COPD is a multifactorial disease, with symptoms and 
structural changes both in the lungs and elsewhere in the 
body. Even within the lungs, there are several pathological 
processes, which may be present in different degrees in dif-
ferent patients and, therefore, there is no single or composite 
summary measure of impaired lung function.3 A PRO instru-
ment, such as a health status questionnaire, provides a means 
of aggregating into a single score the cumulative effect of 
the various pathophysiological processes occurring in differ-
ent organs and systems. It provides an estimate of all of the 
effects of the disease on the patient. These global outcomes 
have advantages over specific outcomes that measure just 
one aspect of the disease, such as FEV
1
 or depression, in 
that they give an overall picture of the impact of the disease 
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or response to therapy.24 This feature may be particularly 
useful when a treatment has multiple beneficial effects, which 
individually may be too small to register as a change on an 
assessment of an individual parameter, but collectively may 
produce noticeable improvement.
PRO instruments for key COPD 
concepts
Breathlessness
Breathlessness is the symptom most frequently reported 
by patients with COPD.25 Persistent breathlessness impairs 
patients’ health-related quality of life, leads to disabil-
ity and causes patients to make considerable lifestyle 
adjustments.26,27 Alleviating breathlessness is therefore a 
primary goal of COPD therapy.1 The most commonly used 
PRO instruments for assessing breathlessness include the 
Medical Research Council dyspnea scale,28 the Modified 
Borg Scale,29 and the Transition Dyspnea Index.30 However, 
these instruments were developed prior to the FDA guide-
lines and are unlikely to satisfy the new FDA requirements 
as stand-alone outcome measures to substantiate claims made 
in product labeling. Briefly, the Medical Research Council 
scale was introduced over 50 years ago for patients with 
chronic bronchitis and comprises a set of five statements 
about levels of breathlessness during daily activities. Patients 
select the statement that most closely corresponds to their 
level of impairment. It is simple to perform, has predictive 
validity, and correlates well with clinical and pulmonary 
parameters, but shows poor responsiveness to intervention.31 
Originally developed in the 1980s, the Modified Borg scale 
is a ten-point scale in which patients simply select a point 
on the scale that matches their perception of their dyspnea. 
The Modified Borg instrument is easy to perform, can be 
administered during exercise, and is responsive to interven-
tion, but correlates less well than the Medical Research 
Council scale with other outcomes.32 The Transition Dyspnea 
Index was developed in 1984 using data from patients with 
COPD, asthma, and interstitial fibrosis.30 It is a validated tool 
that measures changes in the severity of dyspnea in three 
categories, ie, functional impairment, magnitude of task, 
and magnitude of effort. It is sensitive to intervention and 
was originally designed as a physician interview with the 
patient, but a self-administered computerized (SAC) version 
of the Transition Dyspnea Index became available in 2004. 
The SAC Transition Dyspnea Index provides a responsive 
measure of the severity of breathlessness and avoids any 
interviewer interpretation; results are collected and analyzed 
electronically on a continuous scale.33 Comparison studies 
in patients with COPD have shown that the SAC Transition 
Dyspnea Index produces data similar to those obtained with 
the original interviewer-led Transition Dyspnea Index in 
terms of intensity of breathlessness and response to therapy, 
and is more responsive to therapy than the Medical Research 
Council scale.33,34 Other less frequently used breathlessness 
scales include the Chronic Respiratory Disease Question-
naire (CRQ)-dyspnea component and the University of 
California San Diego Shortness of Breath Questionnaire 
(UCSD-SOBQ).35,36 The CRQ-dyspnea component evaluates 
shortness of breath on a scale of 1–7 and allows patients to 
identify activities important to them that are restricted by 
breathlessness. However, as each individial is selecting their 
own unique list of activities that make them breathless, it 
is not standardized and direct comparisons cannot be made 
between patients.37 The current UCSD-SOBQ rates self-
reported breathlessness during activities of daily living for 
24 activities, and is the result of several modifications of a 
questionnaire originally described in 1987. The instrument 
has been shown to be a reliable and valid tool when used to 
assess dyspnea associated with activities of daily living;36 
however, while it has found extensive use in pulmonary 
rehabilitation, it is largely a research instrument.38
Newly developed PRO tools for assessing breathless-
ness include the SOBDA questionnaire, the Global Chest 
Symptoms Questionnaire (GCSQ), the Dyspnea-12, and the 
Dyspnea Management Questionnaire Computer Adaptive 
Test (DMQ-CAT).39
Shortness of Breath with Daily Activities 
questionnaire
The SOBDA is a unidimensional 13-item instrument cur-
rently being developed with input from COPD patients and 
clinical experts for use as a primary or secondary efficacy 
endpoint in clinical trials.19 It is self-administered via an elec-
tronic daily diary, with a weekly average score providing the 
most representative measure of dyspnea. Preliminary studies 
indicate that it is reliable and valid for measuring breathless-
ness with daily activity in COPD patients. Responsiveness to 
intervention and responder threshold is yet to be confirmed, 
and relationships between SOBDA scores and other concepts 
and measures have yet to be elucidated.
Global Chest Symptoms Questionnaire
The GCSQ is a new, validated, and responsive self-
 administered PRO tool developed to evaluate morning 
symptoms in patients with COPD.18 The GCSQ shows good-
to-high reliability and significant correlation with symptoms, 
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use of rescue medication, and health-related quality of 
life. The instrument is able to discriminate differences in 
health-related quality of life between patients, but is insen-
sitive to differences in disease severity. The GCSQ score is 
significantly responsive to changes with treatment, and the 
minimally important difference is estimated to be a change of 
0.15 points. Unfortunately, the GCSQ was developed using 
interviews from only a small number of patients with severe 
COPD and may not fully meet regulatory requirements.
Dyspnea-12
This short instrument for use in COPD, interstitial lung 
disease, and heart failure was developed in 2009 using 
patient consultation and a systematic literature review, with 
subsequent use of Rasch modeling to refine the selection of 
items. It uses a novel approach based upon descriptions of 
breathlessness and has good measurement properties when 
used in its target diseases and asthma.40,41 The minimally 
important difference is yet to be established.
Dyspnea Management Questionnaire Computer 
Adaptive Test
The DMQ-CAT, is a multidimensional instrument using a 
computer adaptive test approach to dyspnea  assessment. 
As a modif ied version of the Dyspnea Management 
 Questionnaire (DMQ), with an expanded bank of 100 items, 
it has been shown to capture reliably and validly the four 
distinct dyspnea domains measured in the DMQ, ie, dysp-
nea intensity, dyspnea-related anxiety, activity avoidance, 
and activity self-efficacy.39 However, further studies testing 
the responsiveness of the DMQ-CAT in detecting dyspnea 
change after COPD treatment are required.
Physical functioning
COPD causes considerable impairment of patients’ physical 
functioning, leading to limitations in their ability to perform 
daily activities, such as personal care, physical exercise, and 
attendance at social events.42,43 The most common complaint 
of patients with COPD is that their condition prevents them 
from completing their favorite activities.25 Because physi-
cal functioning is a broad concept, it must be assessed using 
a multidomain complex PRO tool in order for the effects 
of therapies to be interpreted in a clinically meaningful 
 manner.13 The multidimensional nature of physical function 
in patients with COPD is illustrated in Figure 2.
A number of subjective instruments that aim to quantify 
the amount and intensity of physical activity in daily life have 
been used or adapted for use in patients with COPD, such as 
Functional activities
Household maintenance
Categories Examples
Movement
Family activities
Work
Altruistic avocation
Recreation
Hobbies
Traveling
Contributing to community
Helping family friends
Full-time/part-time
employment
Physical work
Physical activities with
spouse, children or pets
Exercising
Walking
Carrying
Doing repair work
Preparing meals
Cleaning
Figure 2 Categories and examples of functional activities that are valued by patients.48
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Follick’s Diary44 and the Minnesota Leisure Time Physical 
Activity Questionnaire,45 and have been reviewed by Pitta 
et al.46 These instruments have not been thoroughly studied in 
COPD patients and generally lack evidence of validity, reliabil-
ity, and responsiveness in this population.46,47 In addition, the 
suitability of many PRO tools measuring physical functioning 
in the primary care setting has been found to be suboptimal.47
Available PRO tools for measuring physical functioning 
in COPD do not always provide sufficient coverage of the 
concepts under investigation.48,49 New PRO tools are being 
developed to address the unmet need for evaluating physical 
functioning in COPD patients.
PROactive tools
The European Innovative Medicines Initiative PROactive 
project is being undertaken by a consortium of 19 partners, 
comprising academic institutions, a small-to-medium sized 
enterprise, patient organizations, and eight major pharma-
ceutical companies, and is partly funded by the European 
 Commission.16 With formal input from the European Medi-
cines Agency and the FDA, European Innovative Medicines 
Initiative PROactive aims to provide a new PRO instrument 
for measuring physical activity in COPD that is patient-driven, 
valid, reliable, and sensitive to change with interventions. 
Developed from patient interviews, the draft questionnaire 
includes items evaluating the amount of physical activity, 
symptoms experienced during physical activity, and physical 
adaptations that the patient needs to make to cope with the 
activity. The project is due to be completed in 2014.
The Capacity of Daily Living during  
the Morning questionnaire
The CDLM questionnaire is a validated PRO tool for patients 
with COPD, and was developed in 2010 to assess their ability 
to carry out morning activities, which are particularly bother-
some for these patients.18 With this instrument, patients rate 
their ability to perform different morning activities on a five-
point Likert-type scale. Clinical data indicate that the CDLM 
questionnaire is reliable and responsive to therapy, but is unable 
to discriminate disease severity. Furthermore, methodological 
issues, such as the fact that it was developed using interviews 
from only a small group of patients with severe COPD, may 
prevent this tool from meeting regulatory requirements.
London Chest Activity of Daily  
Living questionnaire
The London Chest Activity of Daily Living questionnaire is 
a short questionnaire designed to assess 15 core activities of 
daily living in patients with COPD.50 During the  development 
of this questionnaire over 10 years ago, which involved 
interviews with patients with severe COPD and a literature 
review, items normally present in other instruments were 
specifically excluded because they showed poor retest reli-
ability, and no association with perception of global health or 
activities that were not limited in the majority of patients. The 
London Chest Activity of Daily Living questionnaire shows 
moderate-to-good correlations with other PRO instruments, 
such as the St George’s Respiratory Questionnaire (SGRQ) 
and the Hospital Anxiety and Depression scale, and has 
demonstrated high internal consistency.50
Exacerbations
Exacerbations are a hallmark of COPD and have a substantial 
and often sustained detrimental impact on patients’ health 
status and quality of life.51,52 Reducing the frequency and 
severity of exacerbations is an important goal of COPD 
management and in reducing resource utilization.1,53 The 
unpredictability of exacerbations contributes to the burden 
of disease for COPD patients and increases fear. Moreover, 
fear, anxiety, and depression are all associated with poor 
adherence or noncompliance with medical treatment, an 
increased rate of exacerbations, more frequent readmissions 
to hospital, and higher COPD mortality.54–56 Until recently, 
there was no standardized PRO instrument for assessing 
COPD exacerbations.
EXAcerbations of Chronic pulmonary disease Tool
EXACT is a 14-item daily electronic diary designed to 
measure the severity, frequency, and duration of acute 
exacerbations in clinical trials of patients with COPD and/
or chronic bronchitis. It has been developed by the EXACT-
PRO initiative, which is a collaboration between research 
and clinical specialists in COPD, instrument development 
experts, and FDA representatives.57–59 Initial testing of 
EXACT in an observational study of patients with COPD has 
indicated that it is a reliable, valid, and sensitive tool, with 
good internal consistency.15 Results of FDA and European 
Medicines Agency qualification reviews of PRO instruments 
are expected in 2012.
Health status and quality of life
Improving health status is an important goal of COPD 
management.1,60 Health status and health-related qual-
ity of life are terms that are used rather interchangeably, 
which is not unreasonable given that they both tap into the 
same patient-reported symptoms and impacts. However, 
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there is an argument for using the term “health status” for 
standardized measurement of the impact of the disease, 
since such instruments should be valid for every patient to 
whom they may be administered. The term health-related 
quality of life may be better reserved for describing clinical 
outcome as experienced by the patient, and health status as 
the marker used to measure that outcome.2 Disease-specific 
health status questionnaires have been shown to discriminate 
between different levels of COPD severity.12,61,62 Because 
health status is a multidimensional concept (Figure 3),63 
it requires evaluation with a multidomain PRO instru-
ment to provide useful information about the effects of a 
treatment.
There are numerous PRO instruments designed for 
evaluating health status in patients with respiratory condi-
tions, the most commonly used being the SGRQ and the 
CRQ. Furthermore, several PRO tools aimed specifically 
at assessing health status in patients with COPD have been 
introduced. These tools take into account aspects of the dis-
ease that are most clinically relevant to patients with COPD 
and which may not be measurable by other methods. They 
aim to optimize the sensitivity to changes in health status in 
response to clinical intervention.
St George’s Respiratory Questionnaire 
for patients with COPD
The SGRQ is a self-administered questionnaire that measures 
health status in patients with chronic airflow limitation. It 
contains 50 items, a total score ranging from 0 (perfect health) 
to 100 (most severe status), and three component scores 
encompassing symptoms, activity, and impacts. There was 
significant patient input into its development over 20 years 
ago because each item response is weighted using explicit 
patient-derived weights.64,65 The SGRQ has been shown to 
be reproducible and valid in its ability to detect important 
changes over time.3,61 It has been used in many trials and has 
demonstrated responsiveness to pharmacological therapy 
within 6–8 weeks,66 and was able to identify treatment 
effects maintained over 3–4 years.67,68 Introduced in 2007, 
the COPD version of the SGRQ (SGRQ-C) is a revised and 
slightly shorter version specifically for COPD that produces 
scores directly analogous to those from the original.69 It 
was revised using Rasch analysis of responses from COPD 
patients and validated using data from the original validation 
study. The SGRQ has been used in ECLIPSE, a large 3-year 
biomarker study,70 and has been shown to be responsive to 
therapy.71 A very wide range of translations is available for 
both  versions at http://www.healthstatus.sgul.ac.uk.
Chronic Respiratory Questionnaire
The CRQ is a validated and reliable tool, available as both 
an interviewer-led and a self-administered questionnaire. 
Originally developed in 1987 based on the responses of 100 
patients with COPD, the questionnaire includes 20 items 
across four domains, namely dyspnea, fatigue, emotional 
function, and mastery.72,73 Patients rate their experiences 
with COPD on a seven-point Likert-type scale, ranging 
from 1 (maximum impairment) to 7 (no impairment). It is 
responsive to changes within individuals, but is not suitable 
for comparisons across populations. It may also lack sensi-
tivity in patients with minor symptoms.74 This widely used 
questionnaire is available in several languages.75–78
COPD Assessment Test
The COPD Assessment Test (CAT) was developed in 2009 
to FDA standards using Rasch modeling of data from over 
1500 COPD patients to measure the impact of COPD on 
health status and aid patient-physician communication, 
whilst overcoming the obstacle of having to perform a 
lengthy or complex questionnaire in limited clinic time.79 
It is short and simple, comprising eight items that cover 
a broad range of impacts on COPD patients. Despite its 
brevity, it provides a reliable measure of COPD severity 
and can be used routinely. The CAT demonstrates good 
internal consistency and true interval scaling properties, 
ensuring that it is relevant for global use, and correlates well 
with the SGRQ.79–81 It has been shown to be reliable across 
six European countries.81  Responsiveness to pulmonary 
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Figure 3 Conceptual scheme of domains and variables involved in the assessment of 
quality of life. © 1996, Massachusetts Medical Society. Reproduced with permission 
from Testa MA, Simonson DC. Current concepts: assessment of quality-of-life 
outcomes. N Engl J Med. 1996;334(13):835–840.108
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 rehabilitation has been demonstrated,80 and it has been shown 
to be responsive to recovery from an exacerbation.82 A very 
wide range of language versions is available at http://www.
CATestonline.org.
Clinical COPD Questionnaire
The Clinical COPD Questionnaire (CCQ) is a short, 
easy-to-use tool developed in 2003 with both patient and 
clinical input primarily for assessing health status in the 
primary care setting, but is also useful for measuring 
response to  intervention in clinical trials and for assessing 
clinical improvement following smoking cessation.83 It is 
a self-administered instrument that measures the clinical 
status of the airways, physical impairment, and emotional 
 dysfunction. The CCQ has shown good reliability, validity, 
and responsiveness at the group and individual levels.47 
The CCQ has also been shown to identify patients at risk of 
COPD (Global Initiative for Obstructive Lung Disease stage 
0).83 This questionnaire is available in 64 different languages 
at http://www.ccq.nl.
Living with COPD questionnaire
The Living with COPD (LCOPD) questionnaire is a PRO 
tool designed to assess the patient’s perspective of the over-
all impact of COPD on their daily life.84 Drafted using the 
findings from qualitative interviews and focus groups, the 
questionnaire was refined using Rasch and traditional psy-
chometric analyses to a 22-item instrument. The LCOPD has 
demonstrated good scaling properties and warrants further 
investigation to determine its value in evaluating treatment 
response.
Health authority requirements
Some existing health status tools may not be deemed ade-
quate for determining treatment effects in clinical trials by 
regulatory authorities, because they were developed before 
guidance on PRO instrument development and use became 
available, and they vary widely in the number and type of 
concepts and items measured.85 However, the FDA has 
recently allowed presentation of SGRQ clinical trial data in 
the package insert for indacaterol.
Other concepts of interest
There are several other concepts that are important for COPD 
outcomes, such as cough, sleep disturbance and fatigue. 
Hence, the availability of PRO tools designed to measure 
these concepts may help to elucidate further specific treat-
ment effects.
Cough
Cough is reported to be the exacerbation symptom with the 
greatest impact on patients’ well-being.25 The Cough Severity 
Diary is a simple, seven-item PRO instrument in development 
for use in clinical trials to capture the effects of treatment on 
cough severity from the patient’s perspective.86 Preliminary 
testing in 39 patients with chronic or subacute cough shows 
that the Cough Severity Diary has good correlation with vali-
dation instruments and warrants further investigation.86 The 
Leicester Cough Questionnaire is a self-administered instru-
ment for evaluating health-related quality of life in patients 
with chronic cough.87 Introduced in 2003, it comprises 
19 items with a seven-point Likert-type response scale and 
takes less than 5 minutes to complete. Patients with chronic 
cough were involved with item generation and reduction, it 
has been well validated, and has been shown to be repeatable 
and responsive to change.87,88 Recent data have indicated that 
the minimally important difference for the Leicester Cough 
Questionnaire is a score of 2.5.88
Sleep problems
Patients with COPD frequently experience sleep  disturbance, 
which is often associated with breathlessness.89 It has been 
shown that “sleep difficulties” is the third most frequently 
reported symptom of COPD (after dyspnea and fatigue), 
occurring “almost always” or “always” in 43% of patients.90 
An estimated 50% of COPD patients experience sleep 
problems, which can have significant adverse effects on 
physical and emotional functioning.91 COPD has been shown 
to result in problems with initiating and maintaining sleep, 
excessive daytime sleepiness, altered sleep architecture 
(especially increased arousals), reduced total sleep time 
and decreased sleep efficiency.92 In addition, many patients 
with COPD also have obstructive sleep apnea/hypopnea 
syndrome.93  However, despite the high frequency of sleep 
problems and the impact on patients, there is currently a 
lack of COPD-specific tools for the assessment of sleep in 
patients with COPD.
Fatigue
Fatigue is a common symptom of COPD and has a detrimen-
tal impact on many aspects of patients’ health status.94,95 The 
Manchester COPD Fatigue Scale is a 27-item questionnaire 
created in 2009 to address this symptom, which is not well 
represented in other symptom or health status PRO tools.96 
Developed and refined according to patients’ responses to 
a 57-item pilot scale, it has shown good correlation with 
validation instruments and correlates well with health status 
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and dyspnea, but its responsiveness to intervention is not 
yet known.
Symptom severity
Respiratory symptoms are a defining characteristic of COPD 
but there are no PRO instruments available for assessing 
changes in their daily severity in response to treatment in clin-
ical trials. The EXACT-Respiratory Symptom (EXACT-RS) 
is a scoring algorithm for a subset of 11 items within the 
EXACT to quantify the severity of respiratory symptoms of 
COPD with three subscale scores, assessing breathlessness, 
cough and sputum, and chest symptoms. Developed in 2011 
using qualitative data from COPD patients, this instrument 
shows high reliability and validity, allowing evaluation of 
variation in symptom severity over time.97 Treatment respon-
siveness and scoring interpretation for the EXACT-RS are 
yet to be determined.
Work productivity
The Work Productivity and Activity Impairment question-
naire (WPAI) is a well validated instrument for measuring 
impairments in work and activities and has been adapted for 
several diseases, including ankylosing spondylitis, gastro-
esophageal reflux disease, and irritable bowel syndrome.98–100 
The COPD version of the instrument (WPAI-COPD) is 
a seven-item questionnaire that examines the limitations 
COPD places on patients’ ability to undertake work and 
daily  activities. In a study comparing five different self-
administered health-related quality of life questionnaires, 
the WPAI-COPD was rated “acceptable”, “easy”, or “very 
easy” to use by 84% of patients with COPD.101 Although the 
WPAI is not widely used in patients with COPD and appears 
to be underutilized, a recent international survey incorporated 
items from this questionnaire to help investigate the impact 
of COPD on a working-age cohort.102
Conclusion
COPD is a multifactorial disease, characterized by a variety 
of pulmonary and extrapulmonary changes, which impact 
upon several aspects of a patient’s life. Although lung func-
tion is an essential component of the diagnostic work-up 
for COPD and an appropriate marker for some aspects of 
improvement in response to intervention, a more comprehen-
sive approach to evaluating the disease is called for. PROs 
are now recognized as a crucial element in the assessment of 
COPD, both for determining the impact of the disease itself 
and also for evaluating the success or failure of therapeutic 
interventions. The importance of evaluating the impact 
of COPD in all aspects of patient’s perceived  physical, 
 emotional and mental health, and the responsiveness of 
these elements to clinical intervention is underlined by new 
regulatory guidelines that specify strict criteria in the use of 
PROs to support labeling claims.
Health status questionnaires, such as the SGRQ and the 
CRQ, provide a comprehensive assessment of the overall 
effect of the disease and have been well tested in a variety 
of clinical settings and populations. They are known to be 
responsive to a wide range of therapeutic interventions, and 
can provide an overall measure of the response to treatment. 
Total scores, such as those obtained with the SGRQ, are 
“black box” measurements and provide little or no informa-
tion of the specific nature of the benefit or any insight into 
mechanisms of benefit. A number of more specific tools 
have been developed to evaluate various aspects of the 
disease, although many of these were developed prior to the 
new regulatory guidelines and may only be valid as second-
ary or supportive outcome measures in clinical  trials. Data 
from the development and validation of new and promising 
COPD-specific instruments that are acceptable to regulatory 
authorities are emerging, and new standards in the evalua-
tion of novel therapies for COPD are being set. However, 
it should be appreciated that it takes several  studies and 
many years for that body of evidence to  accumulate. 
New does not necessarily mean better discriminative or 
evaluative properties than old. The recent development 
of the simple eight-item CAT using Rasch methodology 
is a case in point; it correlates very well with the much 
longer SGRQ-C, the scoring of which is complex and uses 
patient-derived item weights.79–81 This suggests that the two 
instruments address the same underlying construct, but, 
despite being developed using an approach that followed 
current FDA guidance, this observation does not mean 
that CAT is “better”, merely that it is shorter. Indeed this 
is another piece of evidence for the validity of the SGRQ, 
even though it is 20 years old.
In many clinical trials a measure of overall treatment 
efficacy is needed and this can be provided by health status 
measures. There is a very large body of published evidence 
concerning the SGRQ in research studies of all kinds. It has 
been accepted by the European Medicines Agency as a symp-
tomatic outcome measure in COPD trials and it is becoming 
accepted as an outcome measure for COPD studies by the 
FDA. A white paper to support that purpose is being put 
together by a consortium working with the COPD Foundation 
in the US. For a shorter measure, both the CCQ and CAT 
have demonstrated validity and responsiveness.
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Ideally, there should be a set of standardized compre-
hensive PRO instruments that are approved by regulatory 
authorities and used consistently during drug development 
and research. The ongoing collaborations with regulatory 
bodies, academia, and the pharmaceutical industry promise 
to address the need for measures of the COPD concepts, 
particular for the tools being developed, for example, 
physical activity in the European Innovative Medicines 
Initiative PROactive project and exacerbation symptoms in 
the EXACT initiative, but significant gaps remain. Several 
individual pharmaceutical companies are committed to the 
continued development of additional PRO tools to ensure 
that relevant treatment effects are captured in clinical trials 
(eg, CDLM, SOBDA). These new instruments may provide 
insights into COPD, particularly in terms of its impact on 
patients, and may reveal new treatment outcomes that have 
been hitherto obscured.
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